Hayley Virgil | Authors

MRD-Based Consolidation Dara-KRd Results in Quick Responses and High Rates of MRD Negativity in Newly Diagnosed Myeloma

September 13, 2021

Patients with newly diagnosed multiple myeloma experienced rapid responses and notable rates of minimal residual disease negativity following minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone.